| 摘要 |
The present invention includes a renal impairment or inner ear disorder inhibitor that includes, as an active component, cilastatin or a pharmaceutically acceptable salt thereof, and is induced via megalin by at least one megalin ligand selected from the group consisting of polymyxins, aminoglycoside antibiotics, glycopeptide antibiotics, cisplatin, and pharmaceutically acceptable salts thereof. |
